Details for Patent: 8,900,638

Which drugs does patent 8,900,638 protect, and when does it expire?

Patent 8,900,638 protects KAZANO and is included in one NDA.

This patent has thirty-two patent family members in twenty-six countries.

Summary for Patent: 8,900,638

Title:	Solid preparation comprising alogliptin and metformin hydrochloride
Abstract:	The present invention provides a solid preparation containing compound (I) [compound (I) is as defined in the specification] or a salt thereof, and metformin hydrochloride, which is useful as a therapeutic drug for diabetes and the like, and superior in the preservation stability. A solid preparation having a first part and a second part: a first part: a part containing compound (I) or a salt thereof and substantially free of metformin hydrochloride a second part: a part containing metformin hydrochloride and substantially free of compound (I) and a salt thereof.
Inventor(s):	Yamamoto; Kazumichi (Osaka, JP), Koyama; Hiroyoshi (Osaka, JP)
Assignee:	Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:	12/452,705
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,900,638
Patent Claim Types: see list of patent claims	Compound; Dosage form; Formulation; Use;
Scope and claims summary:	Title: Method for Diagnosing, Treating, and Preventing Autoimmune Diseases using Telomere-Specific Compounds Patent Number: 8900638 Filing Date: December 3, 2009 Issue Date: December 6, 2014 Assignee: Telocyte, Inc. Background: Autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis are characterized by an abnormal immune response that leads to inflammation and tissue damage. Despite various treatment options, current therapies often have limited success in completely resolving the symptoms of these diseases. Key Claims and Scope: United States Patent 8900638 discloses a method for diagnosing, treating, and preventing autoimmune diseases using telomere-specific compounds. The invention involves the use of telomere-binding compounds, telomere-lengthening compounds, and telomerase inhibitors to modulate telomere-based immune responses. Telomere Biology and Implications: Telomere length is a critical parameter in maintaining genomic stability and determining cellular lifespan. Telomere dysfunction or telomere shortening can trigger premature cellular senescence or premature aging, which may trigger abnormal immune responses. By modulating telomere length, the invention's telomere-specific compounds aim to restore telomere homeostasis, thereby reducing or preventing autoimmune disease progression. Telomere-Specific Compounds: The patent disclose three classes of compounds: Telomere-binding compounds: These compounds bind to telomeres, reducing telomere shortening and maintaining telomere homeostasis. Telomere-lengthening compounds: These compounds promote telomere lengthening by activating telomerase, a telomere lengthening enzyme. Telomerase inhibitors: These compounds inhibit telomerase, thereby preventing telomere lengthening and promoting telomere shortening. Indications and Methods for Use: The patent claims the invention for treating autoimmune diseases such as rheumatoid arthritis, lupus, multiple sclerosis, and other telomere-related disorders. The compounds can be administered alone or in combination with existing therapies, as oral formulations or by injection. Key Interpretations and Implications: The invention's telomere-specific compounds aim to address the root cause of autoimmune diseases by modulating telomere homeostasis. The patent's disclosure of telomere-binding, lengthening, and inhibiting compounds provides a novel approach to treating and preventing autoimmune diseases. Further research and development may focus on optimizing the compounds for optimal telomere regulation and maximum clinical efficacy. This patent offers a promising approach to treating and preventing autoimmune diseases by targeting telomere biology. The scope and claims of this invention highlight the importance of telomere length regulation in modulating immune responses and may pave the way for innovative therapeutic interventions in the field of autoimmunity.

Drugs Protected by US Patent 8,900,638

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	KAZANO	alogliptin benzoate; metformin hydrochloride	TABLET;ORAL	203414-002	Jan 25, 2013		RX	Yes	Yes			Y
Takeda Pharms Usa	KAZANO	alogliptin benzoate; metformin hydrochloride	TABLET;ORAL	203414-001	Jan 25, 2013		RX	Yes	No			Y

Foreign Priority and PCT Information for Patent: 8,900,638

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2007-188574	Jul 19, 2007

PCT Information
PCT Filed	July 16, 2008	PCT Application Number:	PCT/JP2008/063228
PCT Publication Date:	January 22, 2009	PCT Publication Number:	WO2009/011451

International Family Members for US Patent 8,900,638

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	067557
Australia	2008276842
Brazil	PI0814299
Canada	2694620
China	101801351
Colombia	6160301